The 1,000 genome project, the Exome Aggregation Consortium (ExAC) or the Genome Aggregation database (gnomAD) datasets, were developed to provide largescale reference data of genetic variations for various populations to filter out common benign variants and identify rare variants of clinical importance based on their frequency in the human population. Using a TP53 repository of 80,000 cancer variants, as well as TP53 variants from multiple cancer genome projects, we have defined a set of certified oncogenic TP53 variants. This specific set has been independently validated by functional and in silico predictive analysis. Here we show that a significant number of these variants are included in gnomAD and ExAC. Most of them correspond to TP53 hotspot variants occurring as somatic and germline events in human cancer. Similarly, disease-associated variants for five other tumor suppressor genes, including BRCA1, BRCA2, APC, PTEN, and MLH1, have also been identified. This study demonstrates that germline TP53 variants in the human population are more frequent than previously thought. Furthermore, population databases such as gnomAD or ExAC must be used with caution and need to be annotated for the presence of oncogenic variants to improve their clinical utility.
| INTRODUCTION
Predicting the pathogenicity of genetic variants associated with various types of diseases constitutes a major challenge for precision medicine (Evans, Powell, & Berg, 2017; Niroula & Vihinen, 2017) . Assessment of constitutional variants of genes associated with hereditary diseases requires multiple lines of evidence, including the demonstration that the variant is not a nonpathogenic variant present in the population. The situation is less complex in the context of cancer, which is usually associated with somatic variants, as tumor-specific variants can be identified by comparison with matched nontumor DNA from the patients, when available.
However, as tumors are associated with many somatic variations, it is crucial to distinguish true driver variants from the majority of passenger-neutral variants. Multiple databases describing cancer genes are now available and include data from tens of thousands of cancer patients (Yang et al., 2015) . Although constitutional variants of many cancer genes (mostly oncogenes) have rarely been identified, germline variants in several tumor suppressor genes, such as APC (MIM# 191170) or PTEN (MIM# 601728), are associated with familial cancer. The pathogenicity of variants of these genes occurring as germline and somatic events can now be more easily predicted on the basis of data derived from various cancer variants databases.
Regardless of the type of disease, the first step in predicting the deleteriousness of a genetic variant requires an evaluation of the Human Mutation. 2019;40:516-524. wileyonlinelibrary.com/journal/humu frequency of the variant in the general population using various human genetic population databases.
Single-nucleotide polymorphisms (SNPs) represent the most common form of genetic variation in the human genome. SNPs were originally defined as constitutional variations present at a frequency of at least 1% in the general population (http://www. ncbi.nlm.nih. gov/books/NBK21088/; Brookes, 1999; Tennessen et al., 2012) .
SNPs are the mainstay of diversity in species and have been found to be tremendously useful markers for genetic studies. The dbSNP database, created in 1998 and maintained by the NIH, keeps track of SNPs (http://www.ncbi.nlm.nih.gov/SNP/; Sherry et al., 2001 ).
The advent of massively parallel sequencing (next-generation sequencing [NGS] ) has ushered in a new era of analysis of the human population with the recognition that the human genome includes far more SNP than initially suspected, including many nonpathogenic variants at frequencies well below the 1% threshold previously used (Karki, Pandya, Elston, & Ferlini, 2015) . Indeed, the last build of dbSNP (build 151) includes 325 million variants, but many studies have questioned the quality of the various entries (Arthur, Cheung, & Reichardt, 2015; Musumeci et al., 2010) . In contrast, data from the 2,504 individuals of the 1,000 genome project have been highly curated and are frequently used as a reference to remove common genuine variants, as recommended by the American College of Medical Genetics and Genomics (Auton et al., 2015; Richards et al., 2015) . Nevertheless, the small number of entries, as well as the high geographical diversity of this cohort (26 populations, 5 superpopulations), do not allow full coverage of low-frequency SNPs (http://www.internationalgenome.org/data/).
In 2014, the Exome Aggregation Consortium (ExAC) released exome data from 60,706 individuals (Lek et al., 2016) . This new database was designed to be used as a novel reference set for SNP allele frequency. ExAC includes data from the 1,000 genomes project, as well as constitutional data from unrelated individuals sequenced as part of various disease-specific and population genetic studies. In 2016, ExAC was transformed into The Genome Aggregation Database (gnomAD) with the inclusion of new data, leading to a dataset with information from 123,136 exome sequences and 15,496 whole-genome sequences of unrelated individuals (http://gnomad. broadinstitute.org/). ExAC and gnomAD have both been widely used as a substitute or complement of dbSNP and are currently used in multiple analytical pipelines.
One disadvantage of sequencing large population cohorts is the incidental identification of a rare pathogenic germline variant unrelated to the goal of the study (H. L. Blackburn et al., 2015) .
The inclusion of these variants could lead to misinterpretation and these variants should, therefore, be annotated.
In the present study, we analyzed gnomAD for the presence of pathogenic TP53 variants, based on the availability of multiple, welldefined TP53 mutation databases (Leroy et al., 2017) . The first step, using an independent set of cancer-associated variants from various origins, consisted of validating a certified set of pathogenic TP53 variants. The gnomAD was then examined to identify multiple pathogenic TP53 variants, including several hotspot variants found in many cancers. Finally, five other tumor suppressor genes were also examined and pathogenic germline variants were identified in the gnomAD.
| MATERIAL AND METHODS

| Database analysis
The current version of the UMD_TP53 database includes 80,406 variants identified in tumors, cell lines (somatic variants) or in patients with hereditary cancers (germline variants; database freeze October 2017; Leroy et al., 2017) . As most variants are described multiple times in different patients, the database includes 6,872 unique TP53
variants. This database includes TP53 alterations identified by conventional sequencing, as well as alterations identified in NGSbased projects such as the cancer genome atlas (TCGA) (https://p53. fr). A subset derived from this database includes only those studies using conventional Sanger sequencing for the detection of TP53
variants. This dataset comprises 37,295 variants (4,299 unique variants). The use of a specific Sanger dataset avoids redundancies and ensures the specificity of the three datasets described below.
TP53 variants from various databases were downloaded from their respective portals (Table S1) broadinstitute.org/pub/ExAC_release/release0.3.1/subsets/, respectively. For the ExAC database, we used both the full dataset as well as the curated dataset that does not include TCGA data. We observed a number of discrepancies in the coordinates used to define the boundaries of the TP53 gene (Table S2) . Although ExAC and gnomAD used the coordinates defined by Ensembl (ENSG00000141510, 7,661,779-7,687,550 GRCh38, with GenBank (7, 692, 659, 779 GRCh38 with a TP53 gene size of 32,772 bp). To ensure an accurate comparison between the various datasets, data from gnomAD and ExAC were obtained by using the genomic coordinates of the entire TP53 gene defined by RefSeq (Table S2) . | 517 the allele frequency of these variants in CH is low (less than 20%), less than the 50% observed for a normal allelic distribution of an SNP. Depending on the stringency of the criteria used to analyze and filter the SNP data, it is possible that some of these variant found in the population database is indeed due to CH.
In the first step, minimal genomic data, such as genomic coordinates and genetic events, were extracted from each dataset to define the correct annotation according to human genome variation society (HGVS) recommendations. In a second step, variant annotation was validated by using the Name Checker tool developed The activity of TP53 protein variants has been described in detail in a previous report (Kato et al., 2003; Soussi, Kato, Levy, & Ishioka, 2005) . Briefly, haploid yeast transformants containing 2,314 TP53 variants and a green fluorescent protein reporter plasmid were constructed. TP53 activity was tested by measuring the fluorescent intensity of green fluorescent protein that is controlled by various promoter sequences regulated by TP53 after 3 days of growth at 37°C. Wild-type TP53 activity for each promoter was set at 100% and the empty plasmid was set at 0.
| RESULTS
| Defining a curated set of pathogenic TP53 variants
Four different nonoverlapping datasets of TP53 variants were used to define a curated set of pathogenic TP53 variants (Figure 1 ; Table S3 ).
The Sanger dataset includes 4,299 variants extracted from the latest version of the UMD_TP53 mutation database (Leroy, Anderson, & Soussi, 2014) . All these variants were described in studies using Sanger sequencing and were published between 1989 and 2017. The other three sets of TP53 variants are derived from large independent cancer sequencing projects: TCGA (Weinstein et al., 2013) , ICGC (Hudson et al., 2010) , and Zehir's study from the MSK-IMPACT project (Zehir et al., 2017) . Each of these studies described more than 1,000 different TP53 variants at various frequencies in the coding regions or splice sites (+2/−2) of TP53 (Table S3) . A novel set of TP53 variants designated as "cancer shared dataset" (CSD) was created by combining the above four datasets to define a core of 471 recurrent TP53 variants found at least once in each database ( Figure 2a ). As these four datasets are derived from independent studies using different patients and different methodologies, it is highly likely that these 471 shared variants are true recurrent pathogenic variants. The frequency of each F I G U R E 1 Flow chart of the strategy used to identify and analyze shared variants with the various datasets used in this study. gnomAD: Genome Aggregation database; NGS: next-generation sequencing; TCGA: The cancer genome atlas of these variants in the four datasets is strikingly similar and includes all the major TP53 hotspot variants (Table S4 ). The only difference concerns the higher frequency of variants in exons 10 and 11 for the NGS data, as these regions were rarely screened by Sanger sequencing.
The CSD includes 168 variants that lead to the expression of truncated proteins (59 nonsense variants, 53 splice variants, 49 indels, and 7 in-frame indels), which are most likely deleterious for TP53 growth suppressor activity. The remaining 303 single-nucleotide variants include 298 missense variants and 5 synonymous variants. The five synonymous variants are localized in the last base of exons 4, 6, and 9 and are known to drastically impair TP53 splicing (Table S4 ; Soussi, Taschner, & Samuels, 2017; Supek, Miñana, Valcárcel, Gabaldón, & Lehner, 2014) .
The CSD was compared with the 1,144 TP53 variants from the NCBI ClinVar database (Figure 2b ). ClinVar is a freely available, central database including genes and variants of clinical importance and corresponding clinical and experimental evidence for a wide range of genes and related disorders (Landrum et al., 2018) . Of the 471 TP53 variants found in the CSD, 286 are also included in ClinVar with 195 (68%) considered to be either pathogenic or likely pathogenic (Figure 2b ). The remaining variants have been labeled as either uncertain or conflicting. None of the 246 benign TP53 variants described in ClinVar were found in the CSD, an observation that reinforces the quality of this dataset.
The pathogenicity of the missense variants included in the CSD has also been assessed using the prediction scores from dbNSFP (see Section 2; Liu et al., 2016;  Figure 2c ; Figure S1 ). The rank scores of TP53 variants from the CSD are always associated with a high pathogenic score significantly different from the scores of the TP53 variants not included in this dataset (Figure 2c ; Figure S1 ). Envision, a novel predictor algorithm that has been shown to outperform conventional predictors was also used and provided similar results (Gray et al., 2018; Figure 2c whereas approximately one-half of the mutants reported only once has an activity greater than 50% compared with wild-type TP53 (Figure 2d ). This result is in total agreement with our previous analysis of the 2014 release of the UMD_TP53 database (Leroy et al., 2014) . TP53 variants from the CSD also display a significant loss of | 519 activity similar to that of the groups of more frequent TP53 variants in the UMP_TP53 dataset (Figure 2d ). Individual analysis of the residual activity of the 298 missense variants identified in the CSD revealed that most of these variants are fully defective for six different TP53 response elements compared with the other missense variants in the database ( Figure S2A,B) .
Overall, the CSD identified in this analysis includes a high-quality set of frequent pathogenic TP53 variants that can be used as a reference for further analysis.
| Oncogenic TP53 variant is included in gnomAD and ExAC
A total of 3,301 constitutional TP53 variants were extracted from gnomAD, including 307 variants in the coding region of the major transcript (NM_000546). These variants were first compared with data from ClinVar. Although many variants were absent, as expected, the remaining variants were classified as either likely benign or uncertain, while only a few were classified as pathogenic or likely pathogenic ( Figure S3A,B) . Functional analysis of these variants showed that most of them are still active, confirming that they most correspond to benign variants (Figure 2d) . gnomAD variants were then compared with the CSD. A total of 37 TP53 variants were present in both datasets, including 34 missense variants, 2 nonsense variants, and 1 frameshift variant (Figure 1 ). Despite the low frequency of each of these variants in the gnomAD database (ranging from 1 to 10 among the 37 variants leading to a total of 73 individuals with one of these variants), several of these variants correspond to hotspot variants described in human cancer and known to be fully defective for TP53 tumor suppressor activity (Figure 3a) . TP53 variants, such as NM_000546_c.524G>A; NP_000537_p.Arg175His, NM_000546_c.7817C>T; NP_000537_p.
Arg273Cys or NM_000546_743G>A; NP_000537_p.Arg248Gln, have also been shown to be highly oncogenic both in vitro and in vivo in mice knock-in models with multiple gains of function (Jackson & Lozano, 2013; Oren & Rotter, 2010) .
Heat map of TP53 activity shows that the majority of the 34 missense variants are indeed defective for TP53 transactivating activity (Figure 3) . Variant NM_000546_c.672G>T; NP_000537_p.
Glu224Asp does not display any loss of transcriptional activity, but F I G U R E 3 Identification of deleterious TP53 variants in gnomAD. (a) The heat maps correspond to the residual transcriptional activity of the 34 TP53 missense variants found in both gnomAD and the CSD. Each column represents a different transcription promoter and each row represents a different TP53 variant. Activities are displayed from red (lowest) to green (highest). Variant ID using both cDNA (NM_000546.5) and protein (NP_000537.3) nomenclature is shown on the right for each variant. The count of each variant is shown on the right side of the heat map as blue bars for the Sanger database and green bars for gnomAD and ExAC datasets. (b) Same as (a) with the eight missense TP53 variants that have been filtered out in version 2.02 of gnomAD, but still included in the ExAC database (see Section 2 for more information). Stars (red, left): last base exon variants are known to impair TP53 splicing. Although both variants potentially lead to an amino acid substitution, they should be considered to be TP53 null and pathogenic. Arrows (red, right, ExAC column): TP53 variants detected in the ExAC dataset that does not contain TCGA data. ExAC: Exome Aggregation Consortium; gnomAD: Genome Aggregation database; TCGA: The cancer genome atlas this single-nucleotide substitution, localized in the last base of exon 6, is known to be deleterious for TP53 splicing, leading to a TP53 null phenotype, as the putative mutant protein is not expressed (Supek et al., 2014) . This observation illustrates the limitation of certain analytical tools, which predicted that an amino acid change affects protein function. However, it is also possible that a missense variant does not act at the protein level, but rather at the nucleotide level by interfering with the correct assembly of the pre-mRNA splicing machinery. The correct nomenclature for this variant should be NM_000546_c.672G>T; NP_000537_p.?, as recommended by HGVS.
Many different computational variant effect predictors all predicted these variants to be pathogenic despite using algorithms based on protein structure or sequence conservation ( Figure S4 ).
None of these variants were predicted to be benign according to ClinVar ( Figure S3C ).
The gnomAD database includes data from the ExAC database (an aggregation from 60,706 individual exome analyses) and was subsequently completed with data from 123,136 individual exomes.
It also includes whole-genome sequencing data from 15,496 individuals. However, several patient cohorts from ExAC were not included in gnomAD (http://gnomad.broadinstitute.org/). Analysis of TP53 variants from ExAc shows that 28 of the 34 missense variants are present in both datasets at similar frequencies. New variants in gnomAD are likely to be derived from the new datasets that have been added. We also observed that eight TP53 variants identified solely in ExAc are included in the CSD (Figure 3a ). Whether these variants belong to ExAC-specific patient cohorts or have been filtered out in gnomAD is currently unknown.
The gnomAD and ExAC datasets have a highly heterogeneous origin, including multiple studies on various diseases. Notably, these datasets include germline data from patients used by the TCGA consortium for cancer genome sequencing. Due to the association between germline TP53 variants and various cancer predisposition syndromes, it is likely that several pathogenic TP53 variants observed in gnomAD could be derived from the TCGA dataset. Although TCGA data cannot be removed from gnomAD, a version of the ExAC database that does not include TCGA data (cancer-free) is available and was examined for TP53 variants (Figure 3b ). Ten pathogenic TP53 variants were filtered out in ExAC when TCGA data were removed, confirming the high prevalence of TP53 germline mutations in the TCGA dataset (Figure 3b ; Huang et al., 2018) . These variants are still included in gnomAD.
A total of 135 missense TP53 variants found in gnomAD were not detected in the CSD, although they are present at various frequencies in the Sanger dataset ( Figure S5 ). Whether these variants constitute low-frequency TP53 pathogenic variants or uncommon benign constitutional variants remains an open question.
Altogether, our analysis demonstrates that pathogenic TP53 variants are included in both gnomAD and ExAC with a certain degree of heterogeneity between the two datasets.
| Pathogenic variants for other tumor suppressor genes
To determine whether our observation is specific for TP53, the presence of pathogenic variants for other cancer genes was also For each gene, gnomAD data were crossed with ClinVar data and frequency data from the COSMIC database (Table 1; Table S5 ). 
| DISCUSSION
Stringent criteria were used in this study to identify potential pathogenic variants in the gnomAD database, which is the largest dataset of variants detected in the human population. We first identified and validated a set of pathogenic TP53 variants using multiple independent cancer databases. When compared with T A B L E 1 Summary of ClinVar data for variants found in the gnomAD dataset The results of this study highlight two different issues: first, the frequency of TP53 pathogenic variants in the general population.
The frequency of pathogenic germline TP53 variants in the general population has been estimated to be between 1 in 5,000
and 1 in 20,000 Peng et al., 2017) . At least 15-20% of these germline variants have been shown to be de novo mutations, making large-scale studies more complicated, as the lack of family history of cancer will lead to sampling bias for population analysis Renaux-Petel et al., 2018) .
By taking into account the incidence of each variant found in the various datasets, the frequency of germline TP53 variants was 1/831, 1/1,235, and 1/1,899 in ExAC, ExAC without TCGA and gnomAD datasets, respectively. Although the high frequency of pathogenic TP53 variants in ExAC is biased by the TCGA data, the other two datasets should provide a more accurate picture of the frequency of TP53 germline mutations. In view of the highly stringent criteria that we have developed for the detection of pathogenic TP53 variants, it is likely that other less frequent pathogenic variants may also be included in gnomAD. Historically, germline TP53 variants have been identified in Li-Fraumeni syndrome, a very rare inherited familial predisposition to a wide range of often rare cancers (Malkin et al., 1990) . It was subsequently observed that germline TP53 mutations can be associated with other familial cancers, such as breast/ovarian cancer or sarcoma, indicating that these germline TP53 variants are not restricted to this rare syndrome and are more frequent than previously thought (McCuaig et al., 2012) . Despite the high frequency of germline TP53
variants observed in our analysis, the penetrance of these variants is likely to be highly heterogeneous according to the type of variant and the individual's genetic background and lifestyle. Large case-control studies are necessary to fully evaluate the cancer risks associated with all of these mutations.
In the present study, the variants included in all population databases were considered to be true germline alleles derived from both parents. Recent studies have shown that somatic TP53 variants can arise in the hematologic compartment, leading to CH, which is usually observed in older individuals. A high predominance of these clones and insufficiently rigorous SNP analysis can lead to false interpretation. Nevertheless, most TP53 variants found in CH have an allelic frequency of less than 20%, which should avoid the classification of these variants as germline mutations (Mitchell et al., 2018) .
The second issue raised by our results concerns the presence in both the gnomAD and ExAC datasets of TP53 pathogenic variants, as well as pathogenic variants of other genes. In previous work, Kobayashi et al. (2017) identified 14 pathogenic BRCA1 variants in the ExAC database. This problem can introduce significant errors in genomic studies, as the ExAC and gnomAD databases are both used in pipelines to filter common or uncommon SNPs in human populations (Huang et al., 2018) . Both datasets have also been used as a negative, nonpathogenic set for the purposes of training predictive algorithms (Jagadeesh et al., 2016) . Figure 4 summarizes the analysis performed in this study and displays the population frequency of all missense variants found in gnomAD. Although most pathogenic variants are found at frequencies below 0.00005, the use of a threshold of 0.0001 should ensure that no pathogenic variant is selected.
Because these databases are invaluable tools for the detection of rare and/or population-specific SNPs, we believe that careful curation is mandatory to annotate these variants. As such curation cannot be performed on a large scale by any global predictive tools,
we suggest that this procedure should be performed for each gene by a team of specialized curators, as illustrated in the present study. 
